Flat dosing of carboplatin is justified in adult patients with normal renal function

Clinical Cancer Research

Volumn 12, Issue 21, 2006, Pages 6502-6508

  Ekhart, Corine ^a   De Jonge, Milly E ^a   Huitema, Alwin D R ^a   Schellens, Jan H M ^b,c   Rodenhuis, Sjoerd ^b   Beijnen, Jos H ^a,b,c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG MEGADOSE; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CANCER; POPULATION MODEL; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CARBOPLATIN; CREATININE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 33751305679     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1076     Document Type: Article

References (40)

1. Alberts DS, Dorr RT. New perspectives on an old friend: optimizing carboplatin for the treatment of solid tumors. Oncologist 1998;3:15-34.
2. Van Der Vijgh WJF. Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 1991;21:242-61.
3. Kloft C, Siegert W, Beyer J, et al. Toxicity of high-dose carboplatin: ultrafiltered and not total plasma pharmacokinetics is of clinical relevance. J Clin Pharmacol 2002;42:762-73.
4. Duffull SB, Robinson BA. Clinical pharmacokinetics and dose optimization of carboplatin. Clin Pharmacokinet 1997;33:161-83.
5. De Lemos ML. Application of the area under the curve of carboplatin in predicting toxicity and efficacy. Cancer Treat Rep 1998;24:407-14.
6. Huitema ADR, Spaander M, Mathôt RAA, et al. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin. Ann Oncol 2002;13:374-84.
7. Van Warmerdam LJC, Rodenhuis S, van der Wall E, et al. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide, and peripheral stem cell support. Br J Cancer 1996;73:979-84.
8. Shea TC, Flaherty M, Elias A, et al. A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support. J Clin Oncol 1989;7: 651-61.
9. Wright JE, Elias A, Tretyakov O, et al. High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug levels with renal toxicity. Cancer Chemother Pharmacol 1995;36:345-51.
10. Colby C, Koziol S, McAfee SL, et al. High-dose carboplatin and regimen-related toxicity following autologous bone marrow transplant. Bone Marrow Transplant 2002;26:467-72.
11. Kloft C, Siegert W, Jaehde U. Individualized dosing strategy for high-dose carboplatin in patients with germ-cell cancer. Br J Cancer 2003;89:787-94.
12. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7: 1748-56.
13. Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995;87:573-80.
14. Newell DR, Siddik ZH, Gumbrell LA, et al. Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin. Eur J Cancer Clin Oncol 1987;23:1399-405.
15. Harland SJ, Newell DR, Siddik ZH, et al. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res 1984;44:1693-7.
16. Newell DR, Pearson ADJ, Balmanno K, et al. Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. J Clin Oncol 1993;11: 2314-23.
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16: 31-41.
18. Jelliffe RW. Creatinine clearance: bedside estimate. Ann Intern Med 1973;79:604-5.
19. Wright JG, Boddy AV, Highley MS, et al. Estimation of glomerular filtration rate in cancer patients. Br J Cancer 2001;84:452-9.
20. De Jonge ME, Van Den Bongard HJGD, Huitema ADR, et al. Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer. Clin Cancer Res 2004;10:2237-44.
21. Van Warmerdam LJC, Huizing MT, Giaccone G, et al. Clinical pharmacology of carboplatin administered in combination with paclitaxel. Semin Oncol 1997;24: S297-104.
22. Huizing MT, Giaccone G, van Warmerdam LJC, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol 1997; 15:317-29.
23. Huizing MT, van Warmerdam LJC, Rosing H, et al. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J Clin Oncol 1997; 15:1953-64.
24. Zawta B, Delanghe J, Van Den Noortgate N, et al. Arithmetic compensation for pseudo-creatinine Jaffé method and its effect on creatinine clearance results. Clin Chem 2001;47:A148-9.
25. Van Warmerdam LJC, Van Tellingen O, Maes RAA, et al. Validated method for the determination of carboplatin in biological fluids by Zeeman atomic absorption spectrometry. Fresenius J Anal Chem 1995;351: 1820-4.
26. Beal SL, Sheiner LB. NONMEM user's guides. San Francisco: NONMEM Project Group, University of California at San Francisco; 1998.
27. Keene ON. The log transformation is special. Stat Med 1995;14:811-9.
28. Karlsson MO, Sheiner LB. The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 1993;21: 735-50.
29. Kirkpatrick CM, Duffull SB, Begg EJ. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. Br J Clin Pharmacol 1999; 47:637-43.
30. Leger F, Seronie-Vivien S, Makdessi J, et al. Impact of the biochemical assay for serum creatinine measurement on the individual carboplatin dosing: a prospective study. Eur J Cancer 2002; 38:52-6.
31. Chatelut E, Boddy AV, Peng B, et al. Population pharmacokinetics of carboplatin in children. Clin Pharmacol Ther 1996;59:436-43.
32. Madden T, Sunderland M, Santana VM, et al. The pharmacokinetics of high-dose carboplatin in pediatric patients with cancer. Clin Pharmacol Ther 1992;51: 701-7.
33. Shen M, Schilder RJ, Obasaju C, et al. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support. Cancer Chemother Pharmacol 2002;50:243-50.
34. Peng B, Boddy AV, Cole M, et al. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients. Eur J Cancer 1995;31A:1804-10.
35. Nannan Panday VR, Van Warmerdam LJC, Huizing MT, et al. Carboplatin dosage formulae can generate inaccurate predictions of carboplatin exposure in carboplatin/paclitaxel combination regimens. Clin Drug Invest 1998;15:327-35.
36. Okamoto H, Nagatomo A, Kunitoh H, et al. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae. Cancer Chemother Pharmacol 1998;42:307-12.
37. Huitema ADR, Mathôt RAA, Tibben MM, et al. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods. Clin Pharmacol Ther 2000;67:621-30.
38. Van Warmerdam LJC, Rodenhuis S, Ten Bokkel Huinink WW, et al. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin. Cancer Chemother Pharmacol 1996; 37:266-70.
39. Millward MJ, Webster LK, Toner GC, et al. Carboplatin dosing based on measurement of renal function-experience at the Peter MacCallum Cancer Institute. Aust N Z J Med 1996;26:372-9.
40. Thomas F, Séronie-Vivien S, Gladieff L, et al. Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin. Clin Pharmacokinet 2005;44:1305-16.